Business Weekly newspaper’s Post

New Foresite Capital Fund VI at $900M🌟 Foresite Capital has successfully raised $900M for its sixth fund, aimed at investing in life sciences companies. Despite its impressive track record, including 47 IPOs, 28 M&As, and 58 FDA-approved drugs, the San Francisco-based firm faced challenges in its fundraising efforts. The process took two years, reflecting the broader difficulties in venture fundraising in recent years. CEO and founder Jim Tananbaum noted that while almost all of their LPs from Fund V renewed their commitments, they did so with 30% less capital. This created a funding gap that needed to be addressed. To bridge this gap, Foresite hired Hadi Tabbaa, formerly of B Capital and Coatue Management, to lead the firm's investment relations effort and attract new LPs, including family offices from Asia and the Middle East. The firm's Fund V totaled $969M, comprising a $775M core fund and a $194M companion opportunities fund. Foresite was determined to ensure that Fund VI would not be significantly smaller, and their efforts paid off. On Wednesday, the firm announced the closing of its sixth fund at $900M. Foresite began investing from the sixth fund nearly two years ago and has since backed several notable companies. One significant investment was in April, when Foresite Labs, in collaboration with ARCH Venture Partners, invested $1B to incubate Xaira, an AI drug discovery startup. Additionally, the firm participated in the $135M Series A of Latigo Biotherapeutics, Inc., a clinical-stage biotech company developing a non-opioid pain treatment. Last summer, Foresite co-led a $115M Series F round for CG Oncology, a drug discovery company that had a successful IPO in January. The firm plans to back around 20 companies with its Fund VI, writing checks ranging from a few million dollars up to $75M. Foresite Capital's focus remains on the intersection of genomics and artificial intelligence, which Tananbaum believes will revolutionize healthcare by enabling personalized care. "Over a decade ago, we named the firm Foresite because we thought we had an idea of where healthcare was headed," Tananbaum explained. "We felt that it was going to be a combination of genomics and artificial intelligence that would lead to the ability to distribute care individually." These areas continue to be key focal points for the firm as it moves forward. ✅ Looking to raise capital for your #VCfund and increase the international pool of your LPs?   🤝 Need warm #LP introductions?   📝 Selling #secondaries to increase liquidity?   🧐 Looking for co-investments (Series A/Series B)?   ▶ G+QUANT's link for inquiries and fund decks: https://lnkd.in/gjC_EuTE #LifeSciences #VentureCapital #HealthcareInnovation #Genomics #AIinHealthcare 💊💡

Who Will Be the Next Big Disruption in Biotech? 🧬💡 European VC firm Kurma Partners may hold the answer! They've recently unveiled their latest colossal biotech fund of 140 million euros ($154 million), and they aren't stopping there. This marks just the first portion of what this powerhouse intends to be their largest fund yet, setting their sights on up to 20 lucrative biotech investments. Already, three lucky beneficiaries sit within this innovative financial Biodome – a testament to Kurma's ongoing commitment towards empowering Biotech revolutions across Europe. For startups living at technology's cutting edge or pioneer scientists with big ideas and bigger ambitions – this could be your golden ticket. The question now is - who could potentially gain from such an unprecedented scale of investment? Moreover, what sort of transformation will these investments catalyze in the overall landscape of European Biotechnology? The future might seem uncertain but one thing’s for sure - by pushing boundaries in funding and faith given to transformative technologies, firms like Kurma Partners are scripting a new narrative for tomorrow's biotech. Find more about Kurma Partner's ambitious initiative here👇 https://lnkd.in/dZtkNPAx #KurmaPartners #Bioscience #Biotechnology #VCfund #InvestmentInnovation #BiomedicalStartupFunding #EuropeanBioTechNews #VentureCapitalismInEurope #DisruptiveTechnologies #LargestPlannedFund

Who Will Be the Next Big Disruption in Biotech? 🧬💡 European VC firm Kurma Partners may hold the answer! They've recently unveiled their latest colossal biotech fund of 140 million euros ($154 million), and they aren't stopping there. This marks just the first portion of what this powerhouse intends to be their largest fund yet, setting their sights on up to 20 lucrative biotech investments. Already, three lucky beneficiaries sit within this innovative financial Biodome – a testament to Kurma's ongoing commitment towards empowering Biotech revolutions across Europe. For startups living at technology's cutting edge or pioneer scientists with big ideas and bigger ambitions – this could be your golden ticket. The question now is - who could potentially gain from such an unprecedented scale of investment? Moreover, what sort of transformation will these investments catalyze in the overall landscape of European Biotechnology? The future might seem uncertain but one thing’s for sure - by pushing boundaries in funding and faith given to transformative technologies, firms like Kurma Partners are scripting a new narrative for tomorrow's biotech. Find more about Kurma Partner's ambitious initiative here👇 https://lnkd.in/dZtkNPAx #KurmaPartners #Bioscience #Biotechnology #VCfund #InvestmentInnovation #BiomedicalStartupFunding #EuropeanBioTechNews #VentureCapitalismInEurope #DisruptiveTechnologies #LargestPlannedFund

Massachusetts-based VC shop Atlas Venture has drawn together another $450 million fund to be channeled toward innovative biotechs. | Massachusetts-based VC shop Atlas Venture has drawn together another $450 million fund to be channeled toward...

𝐅𝐥𝐚𝐠𝐬𝐡𝐢𝐩 𝐏𝐢𝐨𝐧𝐞𝐞𝐫𝐢𝐧𝐠 𝐄𝐱𝐩𝐚𝐧𝐝𝐬 𝐄𝐢𝐠𝐡𝐭𝐡 𝐅𝐮𝐧𝐝 𝐓𝐚𝐫𝐠𝐞𝐭 𝐛𝐲 $𝟓𝟎𝟎𝐌 Flagship Pioneering, the renowned life sciences investor, is increasing its eighth fund target by $500 million, aiming for $𝟑.𝟓 𝐛𝐢𝐥𝐥𝐢𝐨𝐧. Notable commitments include: - $60 million from Massachusetts' PRIM - $75 million from Texas Municipal Retirement System - $200 million from State of Michigan Retirement System Flagship's strategic expansions and notable partnerships with Pfizer, Novo Nordisk, and Bristol Myers Squibb exemplify the industry's drive towards innovative healthcare solutions. This trend of securing large capital pools is crucial for fostering groundbreaking biotech startups, ensuring sustained innovation and advancement in the life sciences. 𝗜𝗻𝗱𝘂𝘀𝘁𝗿𝘆 𝗖𝗼𝗻𝘁𝗲𝘅𝘁: - 𝐒𝐭𝐫𝐨𝐧𝐠 𝐅𝐮𝐧𝐝𝐫𝐚𝐢𝐬𝐢𝐧𝐠 𝐢𝐧 𝐁𝐢𝐨𝐭𝐞𝐜𝐡 𝐟𝐨𝐫 𝟐𝟎𝟐𝟒:  Many biotech investors, including ARCH Venture Partners ($3 billion), TCGX ($1 billion), and Foresite Capital ($900 million), are also raising substantial funds for 2024. Other significant fundraisers include Decheng Capital ($700 million), Venrock ($650 million), and Innovation Endeavors ($630 million). This indicates strong confidence in the biotech sector’s potential to deliver high returns on investment despite broader market volatility. - 𝐂𝐨𝐥𝐥𝐚𝐛𝐨𝐫𝐚𝐭𝐢𝐯𝐞 𝐆𝐫𝐨𝐰𝐭𝐡: The biotech industry is increasingly leaning on partnerships and collaborations with major pharmaceutical companies. These alliances are essential for driving forward new therapies and technologies. Flagship’s notable partnerships with giants like Pfizer, Novo Nordisk, and Bristol Myers Squibb are prime examples of how collaborative efforts can lead to significant advancements and commercial opportunities in healthcare. - 𝐆𝐥𝐨𝐛𝐚𝐥 𝐄𝐱𝐩𝐚𝐧𝐬𝐢𝐨𝐧: Flagship’s expansion into the UK and Asia is a strategic move to tap into new markets and leverage regional expertise. By establishing a presence in these regions, Flagship can access a broader talent pool, diverse patient populations for clinical trials, and potentially faster regulatory approvals. This global strategy not only diversifies risk but also positions Flagship to capitalize on emerging biotech hubs outside the traditional US market.

🚨 Major Milestone for Biotech Investing! 🚨 ARCH Venture Partners, the Chicago-based venture capital firm, has just closed ARCH Venture Fund XIII at over $3 billion! 💰 What’s the focus? 👉 This fund will drive the founding and growth of early-stage biotech companies aiming to prevent, detect, and cure disease. 🧬🔬 Who’s leading the charge? Managing Directors: • Robert Nelsen • Keith Crandell • Kristina Burow • Mark McDonnell • Steve Gillis • Paul Berns 👏 Fund XIII investments already include exciting companies like: • Arsenal Biosciences, Inc. • Metsera • Mirador Therapeutics • Xaira Therapeutics 🌟 This follows their successful $2.975 billion Fund XII from June 2022. The momentum continues! 💥 Why it Matters: ARCH Venture Partners is a key player in shaping the future of biotech innovation, fueling groundbreaking discoveries and pushing the boundaries of healthcare and life sciences. 🧠💡 📢 Stay tuned to Future Techly for the latest updates on this groundbreaking initiative and the latest in tech and business! 💥 Source: FinSMEs #VentureCapital #Biotech #HealthcareInnovation #LifeSciences #ARCHVenture #Investment #FutureOfHealth #FundXIII #Startups #Innovation #FutureTechly

Claris Ventures Secures Partnership with Exor Ventures! Claris Ventures, an Italian venture capital firm focused on biotech, and Exor Ventures, the VC investment arm of Exor N.V., are collaborating on a new initiative to develop innovative #pharmaceuticals in partnership with Italian universities and research centres.✍🏻 Claris Ventures and Exor Ventures will be seeking potential #drugs and preclinical candidates to add to their development pipeline in the coming months. Researchers from all over Italy are invited to submit ideas and projects via the initiative's online portal. Emphasis will be placed on the expertise of the proposing teams and the availability of preclinical models that allow rapid pharmacological optimization to maximize the synergy between academic research and development activities.💡 The initiative will first focus on development programs originating from the Italian ecosystem, while also considering collaborations with universities and research centres abroad with which Claris Ventures and Exor Ventures have previously worked to establish new biotech companies.📈 Follow Arcadia to learn more about Italian VC!

Eli Lilly and Andreessen Horowitz (a16z) are launching a $500 million Biotech Ecosystem Venture Fund. This powerhouse partnership aims to fuel disruptive science and back ambitious leaders in the industry. Combining a16z's sourcing prowess with Lilly's R&D expertise and capital, the fund will target cutting-edge therapeutic platforms and tech companies. Excited to see this collaboration! 🧬💡👏 https://lnkd.in/gH7j8xY9

ICYMI - The biotech funding ecosystem is complex, with multiple players working together to advance breakthrough medicines. At the heart of this system are Limited Partners (LPs)—the rarely discussed but crucial players who ignite the funding flywheel that drives biotech innovation. Alok Tayi, PhD shares insights about investing in biotech venture capital funds in this post: https://hubs.ly/Q02_9T2H0 #Biotech #Venturecapital #VC #Limitedpartners #LPs #Biotechinvesting #Investmentstrategies #Lessonslearned #Drugdevelopment #ROI #Emergingtechnologies #Patientcapital #Impactinvesting

❗ €123M Investment Opportunity for 7 Early-Stage Life Science Start-ups Key info below ⬇ Who: Seroba. Seroba Fund IV HQ: Dublin, Paris, and Milan Amount of Capital Deployed: €123 million Number of Investments Planned: Aims to make up to 12 investments in total (already invested in 5 companies). Focus Areas: early-stage investments in life sciences companies Geography Focus: Western Europe and selectively in North America Investors Supporting: European Investment Fund (EIF), Ireland Strategic Investment Fund (ISIF), Enterprise Ireland (EI), Allied Irish Banks (AIB), CDP Venture Capital (U.S. corporate entity) and several family offices. https://lnkd.in/g7iN6cCN #venturecapital #healthtech #biotech #fundraising #europe